|
C4ORF29 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.1483036743698E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.25160026576543E-10 |
| Normal-vs-Stage2 |
1.92944999999334E-05 |
| Normal-vs-Stage3 |
1.2723999631703E-09 |
| Normal-vs-Stage4 |
7.15119996552716E-09 |
| Stage1-vs-Stage2 |
8.387200E-01 |
| Stage1-vs-Stage3 |
1.611030E-01 |
| Stage1-vs-Stage4 |
2.080800E-01 |
| Stage2-vs-Stage3 |
2.812600E-01 |
| Stage2-vs-Stage4 |
2.450400E-01 |
| Stage3-vs-Stage4 |
8.915600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.40814051927418E-12 |
| Normal-vs-AfricanAmerican |
3.516900E-03 |
| Normal-vs-Asian |
2.17819999999147E-05 |
| Caucasian-vs-AfricanAmerican |
1.701370E-01 |
| Caucasian-vs-Asian |
3.260600E-01 |
| AfricanAmerican-vs-Asian |
5.936000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.46380019216963E-10 |
| Normal-vs-Female |
1.55309987093233E-10 |
| Male-vs-Female |
6.865000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.02759997680602E-09 |
| Normal-vs-Age(41-60Yrs) |
3.4911999957643E-09 |
| Normal-vs-Age(61-80Yrs) |
6.99839997064799E-09 |
| Normal-vs-Age(81-100Yrs) |
2.375900E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.811600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.821200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.731210E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.576600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.001600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.597400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.155900E-03 |
| Classical-VS-Follicular |
8.659400E-01 |
| Classical-VS-Other |
7.083800E-01 |
| Classical-VS-Normal |
4.52969994846342E-10 |
| Tall-VS-Follicular |
1.881830E-02 |
| Tall-VS-Other |
2.763600E-01 |
| Tall-VS-Normal |
1.86650028766167E-10 |
| Follicular-VS-Other |
8.017800E-01 |
| Follicular-VS-Normal |
2.01970000002216E-06 |
| Other-VS-Normal |
9.899100E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.07540010019625E-10 |
| Normal-vs-N1 |
3.46500000025785E-07 |
| N0-vs-N1 |
9.226800E-01 |
|
|
